Norovirus Gastroenteritis

Gastroenterology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Vaxart
VaxartSOUTH SAN FRANCISCO, CA
2 programs
2
VXA-G1.1-NNPhase 11 trial
VXA-G1.1-NN Oral VaccinePhase 1Vaccine1 trial
Active Trials
NCT02868073CompletedEst. Oct 2017
NCT03125473CompletedEst. May 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
VaxartVXA-G1.1-NN Oral Vaccine
VaxartVXA-G1.1-NN

Clinical Trials (2)

NCT03125473VaxartVXA-G1.1-NN Oral Vaccine

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Start: Apr 2017Est. completion: May 2018
Phase 1Completed

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Start: Jul 2016Est. completion: Oct 2017
Phase 1Completed

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space